Regarding FGFR4, one key divergence in our work from D’Agosto et al. [43], who show a tumor suppressive role for FGFR4 in PDAC, is the selection of model systems and FGFR4 inhibitor. The gene discussed is FGFR4; the disease is neoplasm.